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Peroxisome proliferator-activated receptor-alpha (PPARA) has
been shown to increase fatty acid oxidation and decrease cytokine
levels and has been implicated in insulin production. Genetic var-
iants of PPARA have been associated with cardiovascular disease,
obesity and type II diabetes mellitus. Although no research to date
has investigated the possible link between PPARA and breast can-
cer, the function of this gene suggests that it could play a role in
breast cancer development. Six PPARA polymorphisms were eval-
uated in association with incident breast cancer in a population-
based case–control study (n 5 1073 cases and n 5 1112 controls)
using unconditional logistic and multilevel regression and haplo-
type-based analyses. The odds of breast cancer were doubled
among women with PPARA polymorphism rs4253760 (odds ratio
5 1.97 for rare versus common homozygote alleles; 95% confi-
dence interval: 1.14, 3.43). This association remained constant
with the inclusion of all interrogated polymorphisms studied in
hierarchical models. No additive interactions with body mass in-
dex or weight gain were present, but there was some evidence of
interaction between PPARA variants and aspirin use, defined as
use at least once per week for 6 months or longer. Fourteen hap-
lotypes were imputed with frequencies >1% among postmeno-
pausal women, but no statistically significant differences in
haplotype frequencies between cases and controls were evident.
Our results are the first to evaluate the relationship between
PPARA and breast cancer incidence and suggest that replication
in an independent cohort is warranted.
Introduction
The peroxisome proliferator-activated receptor (PPAR) family is
composed of three nuclear hormone receptor genes: PPAR-gamma,
peroxisome proliferator-activated receptor-alpha (PPARA) and PPAR-
delta. In general, nuclear hormone receptors encode proteins that in-
duce gene transcription by binding to the promoter region of a target
gene. PPARs are activated when small lipophilic hormones (ligands)
bind to a ligand-specific nuclear hormone receptor (1). PPARA li-
gands include palmitic acid, arachidonic acid and stearic acid in ad-
dition to compounds such as fenofibrate, bezafibrate and non-steroidal
anti-inflammatory drugs (2,3).
PPARA is primarily expressed in organs with high fatty acid oxi-
dation rates (3,4), such as the liver, kidney, heart, brown adipose tissue
and, in small quantities, white adipose tissue (2). PPARA has also
been found in human breast cancer cell lines, where its activation
has been associated with increased proliferation (5). PPARA has been
shown to regulate lipid metabolism by controlling the uptake and
oxidation of fatty acids (3). This regulation can lead to an excess of
free fatty acids, which may contribute to insulin resistance (6). Fi-
brates, which are PPARA agonists, have also been shown to reduce the
expression of multiple cytokines, including interleukin-6, fibrinogen
and C-reactive protein in humans (3).
Two PPARA isoforms have been characterized (PPARA1 and
PPARA2). Both isoforms are expressed in human tissue (7,8).
PPARA1 encodes the entire gene, whereas PPARA2 is truncated at
exon 6. This truncation results in the absence of the ligand-binding
domain in the gene’s protein and, consequently, prevents activation by
the ligand. Therefore, all study inferences pertain to PPARA1 because
of its protein’s known activity.
Given its role in energy homeostasis, it seems feasible that genetic
variation in PPARA could influence disease incidence. The epidemi-
ologic literature has focused on a functional polymorphism that re-
sults in a leucine to valine substitution at codon 162 of exon 5 (L162V,
rs1800206) and a subsequent cytosine to guanine base change in the
DNA-binding domain region of PPARA protein. This missense poly-
morphism has been shown to have a functional impact based on
cotransfection assays; specifically, the V162 allele showed elevated
ligand-dependent transcription activity compared with the L162
allele (9).
Although no research to date has investigated the possible link
between PPARA and breast cancer, the biology and epidemiology of
the gene suggest that it could play a role in breast cancer incidence.
Genetic variants ofPPARA have been linked to lipoprotein levels (10–12),
cardiovascular disease (13–15), obesity (16,17) and type II diabetes
(18–20). These conditions arise through etiologic mechanisms that
may also be relevant to breast carcinogenesis, including inflammation
and insulin resistance. Therefore, the goals of this study were to
examine the association between PPARA genetic polymorphisms
and breast cancer development using single polymorphism and
haplotype-based approaches and semi-Bayesian techniques. Interac-
tions with body mass index (BMI), weight gain, aspirin use and
menopausal status were also explored.
Materials and methods
To evaluate the study aims, we utilized data and samples from the Long Island
Breast Cancer Study Project (LIBCSP), a large population-based case–control
study; details of the parent study population and data collection methods have
been published previously (21). The study protocol was approved by the in-
stitutional review boards of participating institutions.
Study population
English-speaking women newly diagnosed with a primary in situ or invasive
breast cancer between 1 August 1996 and 31 July 1997 were eligible to be
study cases, if they were 20 years of age or older at diagnosis and were
residents of Nassau or Suffolk counties on Long Island, New York. Cases were
identified through daily contact with the 33 Long Island and New York City
hospitals that served women with breast cancer in these two counties. Physi-
cian permission was obtained prior to case contact.
Controls were randomly selected from among English-speaking female res-
idents of the same two Long Island counties and were frequency matched to the
expected age distribution of case subjects by 5-year age group. Potentially
eligible controls were identified by Waksberg’s method of random digit dialing
(22) for women ,65 years of age and by Health Care Finance Administration
rosters for women 65 years of age.
Participants in the LIBCSP included 1508 (82.1%) eligible case women and
1556 (62.7%) eligible control women. Study subjects ranged in age from 24 to
98 years, and 93.8% of cases and 91.8% of controls were Caucasian, whereas
4.6% of cases and 5.5% of controls were African-American. Approximately
Abbreviations: BMI, body mass index; CI, confidence interval; LIBCSP, Long
Island Breast Cancer Study Project; OR, odds ratio; PGA, programs for geno-
mic applications; PPAR, peroxisome proliferator-activated receptor; PPARA,
peroxisome proliferator-activated receptor-alpha; SNP, single-nucleotide
polymorphism.
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68% of cases and 67% of controls were postmenopausal (n 5 1010 and 993,
respectively).
Exposure assessment
Questionnaire. Case–control interviews were administered by trained inter-
viewers in respondents’ homes. Interviews took an average of 101 min to
complete. In previous analyses, weight gain, particularly after age 50, was
positively associated with postmenopausal breast cancer (23), and aspirin
use was inversely associated with breast cancer among women of all ages
(24). Other factors found to be associated with breast cancer in the LIBCSP
have also been described previously (21).
Biologic specimens. Among respondents who completed the interview, 73.0%
of cases and 73.3% of controls donated a blood sample. DNA was isolated
using methods described previously (25). Of the 1102 cases and 1141 controls
who donated blood, 19 (1.7%) and 22 (1.9%), respectively, were later found to
have insufficient DNA. Thus, there were a total of 1083 case and 1119 control
samples available for genotyping. For analyses restricted to postmenopausal
women, genotyping was available for 708 cases and 692 controls.
Genetic polymorphisms
Selection of tagging single-nucleotide polymorphisms. Tag single-nucleotide
polymorphisms (SNPs) were selected to represent comprehensive coverage of
the PPARA gene by binning SNPs with a minor allele frequency .0.10 and an
estimated minimum pairwise correlation of 0.80. For PPARA, sequence data
were available for 23 European American and 24 African-American Coriell
samples on the University of Washington-Fred Hutchinson Cancer Research
Center Variation Discovery Resource website (http://pga.gs.washington.edu/).
Haplotype-tagging SNPs were identified using the programs for genomic ap-
plications (PGA) LDSelect Program (26) run for European Americans only
(given the relative racial homogeneity of the LIBCSP population). This pro-
gram has been shown to select a maximally informative set of common SNPs
that distinguish 80% of common haplotypes and is based on the r2 linkage
disequilibrium statistic (27). When multiple possible tag SNPs were identified
for a bin, SNPs located in the exon, promoter and 3# untranslated regions were
given priority. Because of its low prevalence but functional importance, L162V
was forced into the program. Based on this program, 14 PPARA SNPs were
identified for genotyping (Table I).
Genotyping. Genotyping was conducted at Columbia University, New York, NY.
All LIBCSP DNA samples are available on 96-well master plates. Approximately
10% of the samples on each plate were duplicates, and laboratory personnel were
blinded to case–control and duplicate status. Genotyping was carried out using
iPLEX technology (Sequenom, San Diego, CA) on a MassARRAY Compact
Analyzer. This multiplex method uses the mass of the incorporated nucleotide
for identification of genotype. For SNPs that could not be multiplexed (rs4253623
and rs4253699), Taqman (Applied Biosystems, Foster City, CA) assays were de-
veloped and were run on an ABI 7500 Real-Time PCR system.
Kappa statistics were estimated to determine concordance between blinded
repeat samples on each plate, and only those SNPs with a minimum kappa
statistic of 0.90 were included in analyses. Six of the 14 identified tag SNPs for
PPARA met this criterion (Table II).
Statistical methods
Hardy–Weinberg equilibrium was tested among controls to ensure that as-
sumptions of parametric statistical tests were met using a permuted version
of the exact test in SAS/Genetics version 9.1 (Cary, NC) (28,29). Pairwise
linkage disequilibrium (30,31) for the six assayed SNPs was determined using
Haploview 4.0 (32). Unconditional logistic regressions including individual
PPARA SNPs and all SNPs together were conducted using SAS. Main gene
effects were modeled by using the full genotype model and by combining
heterozygotes and rare homozygotes. All models were adjusted for age, the
frequency-matched variable, and common homozygotes were the reference
group for all analyses. Linear trend tests for allelic effects were also performed
by coding each genotype as 0, 1 or 2 based on the number of risk alleles.
Separate genetic models were also used to estimate effects among postmeno-
pausal women only. We hypothesized a priori that the gene’s effect would be
most pronounced in postmenopausal women because of the relationship be-
tween obesity and breast cancer incidence in these women (33,34).
In addition to conventional unconditional logistic regression modeling, hi-
erarchical modeling using a semi-Bayesian approach was performed among all
women and among postmenopausal women only. SAS IML commands de-
veloped by Witte et al. (35) were used to fit the multilevel models. Hierarchical
models assumed that all SNPs were exchangeable. The first hierarchical model
specified a s2, or prior residual variance, of 0.169, whereas the second hierar-
chical model assumed a s2 of 0.345. A residual variance equal to 0.345 speci-
fies that the odds ratio (OR) will fall within a 10-fold range with 95%
confidence, whereas a s2 of 0.169 specifies a 5-fold range.
Confounders were chosen a priori using directed acyclic graphs. Race
(White/non-White), family history of breast cancer (yes/no) and Jewish eth-
nicity (Jewish/non-Jewish) were examined as potential confounders based on
the directed acyclic graphs. Covariates that resulted in a 10% or greater change
in the beta coefficient of the genotype effect estimate were considered con-
founders. Using this criterion, no confounders were identified.
Product interaction terms were added to conventional logistic and Bayesian
models for gene variants and aspirin use, defined as use at least once per week
for 6 months or longer (among all women), and for BMI at reference and
weight gain since age 50 (among postmenopausal women). Due to small
sample sizes, heterozygotes and rare homozygotes were combined for all in-
teraction models. Interactions were considered for each SNP separately with
adjustment for all other SNPs and age. Weight gain models were also adjusted
for BMI at age 50 to account for the potential influence of body mass on weight
gain. Interaction contrast ratios and 95% confidence intervals (CIs) were cal-
culated to assess departures from additive risks (36).
Haplotype reconstruction was performed using an expectation maximization
algorithm (37). Expectation maximization haplotype inference uses an indi-
vidual’s genotype data to impute the probability of having a certain haplotype
pair (38). Haplotype-specific ORs and 95% CIs were estimated relative to all
other haplotypes for all women and for postmenopausal women only. All
haplotype analyses were conducted using unconditional logistic regression in
SAS/Genetics.
Results
Six PPARA SNPs were included in analyses: rs135542, rs1800206,
rs4253623, rs4253699, rs4253755 and rs4253760 (as ordered in
Figure 1). All six SNPs were in Hardy–Weinberg equilibrium, and
minor allele frequencies ranged from 5 to 22.4% (Table II). We found
very low correlation between the PPARA polymorphisms (Figure 1),
suggesting that the PGA population is an appropriate reference for tag
SNP selection in the LIBCSP.
As shown in Table II, PPARA polymorphism rs4253760 was asso-
ciated with nearly a 100% relative increase in the risk of postmeno-
pausal breast cancer (OR 5 1.97 for rare versus common
homozygotes; 95% CI: 1.14, 3.43) and showed evidence of linear
trend (P5 0.02). Consistent findings were noted when all SNPs were
assessed in one model and also for the hierarchical models (Table III).
In general, hierarchical models produced more precise estimates
compared with conventional analyses. This effect is most evident for
the most unstable estimates, such as SNPs with a low prevalence
in this population. For example, the OR for the association comparing
rare to common homozygotes in rs1800206 was 4.14 (95% CI: 0.43,
39.79) among postmenopausal women, adjusting for all other PPARA
SNPs (model labeled Conventionalb in Table III); using multi-
level modeling, this OR decreased to 1.29 (95% CI: 0.58, 2.87;
Hierarchicald).
Table I. PPARA haplotype-tagging SNPs identified using LDSelect and the
PGA European American population as the reference panel




rs4253730 Intron 3 A . G 0.182
rs4253760b Intron 6 T . G 0.196
rs4253705 Intron 2 T . C 0.190
rs135543 Intron 2 G . A 0.283
rs135542b Intron 2 A . G 0.205
rs4253649 Not validated C . G 0.370
rs4253758 Intron 6 T . C 0.217
rs4253699b Intron 2 T . C 0.182
rs4253655 Intron 2 G . A 0.143
rs4253681 Intron 2 T . C 0.136
rs4253755b Intron 5 G . A 0.130
rs4253706 Intron 2 G . A 0.119
rs4253623b Intron 2 A . G 0.109
rs1800206b Exon 5 Leu . Val C . G 0.022
aSequence data on 23 European American Coriell samples are available on
the University of Washington-Fred Hutchinson Center Research Center
Variation Discovery Resource (PGA) website (http://pga.gs.washington.edu/).
bSNPs included in analyses.
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Table II. Summary table of ORs for association between six PPARA polymorphisms and breast cancer risk by menopausal status in LIBCSP
Genotype Genotypea MAFb Cases, n (%)c Controls, n (%)c P for trendd ORe 95% CI
All women
rs135542 AA 0.224 602 (59.4) 634 (59.3) 0.90 1.00
AG 370 (36.5) 392 (36.7) 1.01 0.84, 1.21
GG 41 (4.1) 43 (4.0) 1.01 0.65, 1.57
AG þ GG 411 (40.6) 435 (40.7) 1.01 0.85, 1.21
Total 1013 1069
rs1800206 (L162V) CC (L/L) 0.054 927 (89.7) 973 (89.7) 0.72 1.00
CG (L/V) 100 (9.7) 109 (10.1) 0.97 0.73, 1.30
GG (V/V) 7 (0.7) 3 (0.3) 2.44 0.63, 9.50
L/V þ V/V 107 (10.4) 112 (10.3) 1.01 0.76, 1.34
Total 1034 1085
rs4253623 AA 0.123 811 (77.5) 849 (77.0) 0.77 1.00
AG 218 (20.8) 236 (21.4) 0.97 0.79, 1.19
GG 17 (1.6) 17 (1.5) 0.98 0.49, 1.93
AG þ GG 235 (22.5) 253 (23.0) 0.97 0.79, 1.19
Total 1046 1102
rs4253699 TT 0.220 624 (60.0) 671 (61.5) 0.52 1.00
CT 358 (34.4) 362 (33.2) 1.06 0.88, 1.27
CC 58 (5.6) 59 (5.4) 1.07 0.73, 1.57
CT þ CC 416 (40.0) 421 (38.6) 1.06 0.89, 1.27
Total 1048 1092
rs4253755 GG 0.120 803 (76.5) 845 (77.4) 0.64 1.00
AG 231 (22.0) 231 (21.2) 1.05 0.85, 1.29
AA 16 (1.5) 16 (1.5) 1.05 0.52, 2.12
AG þ AA 247 (23.5) 247 (22.6) 1.05 0.86, 1.29
Total 1050 1092
rs4253760 TT 0.186 675 (66.2) 713 (67.2) 0.41 1.00
GT 293 (28.7) 302 (28.5) 1.02 0.84, 1.24
GG 52 (5.1) 46 (4.3) 1.25 0.83, 1.87
GT þ GG 345 (33.8) 348 (32.8) 1.05 0.88, 1.26
Total 1020 1061
Postmenopausal
rs135542 AA 0.220 395 (59.0) 397 (60.0) 0.61 1.00
AG 247 (36.9) 239 (36.1) 1.07 0.85, 1.35
GG 27 (4.0) 26 (3.9) 1.04 0.59, 1.81
AG þ GG 274 (41.0) 265 (40.0) 1.07 0.86, 1.33
Total 669 662
rs1800206 (L162V) CC (L/L) 0.052 610 (89.3) 609 (89.7) 0.51 1.00
CG (L/V) 68 (10.0) 69 (10.2) 1.01 0.71, 1.44
GG (V/V) 5 (0.7) 1 (0.2) 5.07 0.59, 43.71
L/V þ V/V 73 (10.7) 70 (10.3) 1.06 0.75, 1.51
Total 673 679
rs4253623 AA 0.132 533 (77.4) 522 (75.9) 0.43 1.00
AG 145 (21.0) 150 (21.8) 0.96 0.74, 1.24
GG 11 (1.6) 16 (2.3) 0.66 0.30, 1.45
AG þ GG 156 (22.6) 166 (24.1) 0.93 0.72, 1.20
Total 689 688
rs4253699 TT 0.217 411 (59.8) 425 (62.2) 0.62 1.00
CT 243 (35.4) 220 (32.2) 1.13 0.90, 1.42
CC 33 (4.8) 38 (5.6) 0.92 0.56, 1.49
CT þ CC 276 (40.2) 258 (37.8) 1.10 0.88, 1.37
Total 687 683
rs4253755 GG 0.113 532 (76.3) 535 (78.8) 0.29 1.00
AG 153 (22.0) 135 (19.9) 1.12 0.86, 1.46
AA 12 (1.7) 9 (1.3) 1.36 0.57, 3.27
AG þ AA 165 (23.7) 144 (21.2) 1.14 0.88, 1.47
Total 697 679
rs4253760 TT 0.168 441 (65.0) 454 (69.6) 0.02 1.00
GT 199 (29.4) 177 (27.2) 1.14 0.90, 1.46
GG 38 (5.6) 21 (3.2) 1.97 1.14, 3.43
GT þ GG 237 (35.0) 198 (30.4) 1.23 0.98, 1.55
Total 678 652
aThe combined heterozygotes and rare homozygotes were modeled separately and compared with common homozygotes.
bMinor allele frequency (MAF) calculated among controls.
cMay not add up to 100.0 due to rounding.
dP-value for trend was calculated by coding each genotype as 0, 1 or 2 based on the number of risk alleles.
eAdjusted for age, measured in 5-year intervals.
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Statistically significant departures from expectations for additive
risks (a 5 0.05) with aspirin use were estimated for rs135542 and
rs4253699, but comparable departures from additivity were evident
for all SNPs except rs1800206 (Table IV). Among postmenopausal
women, there was no evidence of interaction by BMI at reference or
by weight gain since age 50, both measured as three-level categorical
variables, with no consistent pattern of elevated additive effects with
increasing levels of obesity (results not shown).
The haplotype reconstruction and analysis created 12 haplotypes
with frequencies .1% from the six SNPs analyzed in all women and
14 haplotypes in the postmenopausal women. Haplotype distributions
were similar between cases and controls among all women (data not
shown) and among postmenopausal women only (Table V). Due to the
low prevalence of selected haplotypes in this population, effect esti-
mates were imprecise, particularly those for associations among post-
menopausal women only. For example, although the OR for haplotype
10 among postmenopausal women (n 5 30 cases and 11 controls)
was elevated relative to all other haplotypes, the 5-fold width of the
CI indicated substantial imprecision (OR 5 5.02; 95% CI: 1.45,
17.39).
Discussion
We found that the PPARA genetic polymorphism rs4253760 was as-
sociated with a 2-fold increase in the odds of postmenopausal breast
cancer. This association persisted in the hierarchical models that were
adjusted for the other five PPARA SNPs. This finding is consistent
with our prior expectation of a more pronounced effect in postmen-
opausal women. rs4253760 is located in intron 6 and tags 10 SNPs
(minor allele frequency . 10%) based on LDSelect and PGA data.
This polymorphism may be correlated with the causal SNP in the
PPARA gene, although it does not tag any non-synonymous coding
polymorphisms and the haplotype analyses with the rare variant of
rs4253760 are not supportive of a causal effect.
Our results also suggest that PPARA genetic polymorphisms may
modify protective effects of aspirin use. In the LIBCSP population,
aspirin use was associated with a 20% reduction in the odds of breast
cancer (24) overall. In this study, inverse associations with non-
steroidal anti-inflammatory drug use were evident only among women
with referent genotypes of rs4253623, rs4263699, rs4253755 and
rs4253760 or the homozygous variant genotype for rs135542.
Despite the additional computational complexity, hierarchical
modeling offers two advantages over conventional logistic regression:
(i) the shrinkage estimation method reduces type II error rate (39,40)
and (ii) it reduces instability in the effect estimates due to multiple
correlated exposures, such as multiple SNPs in the same model (40).
For this study, two different s2 values were considered: 0.169 and
0.345. The difference between the hierarchical and conventional mod-
els was most apparent for the fully specified conventional model,
where each genotype was modeled simultaneously. Here, the s2
0.169 models consistently produced estimates that were closer to
the null and more precise than either the s2 0.345 hierarchical models
or the conventional logistical models.
It has become increasingly apparent that studies of a single poly-
morphism are not necessarily the best approach to identify deleterious
variants (41). Haplotypes that use tag SNPs selected from bins com-
prehensively assess variation over the entire gene to identify cis–cis
interactions, where tag SNPs are interacting on the same chromosome
to increase disease risk. Our study implicates haplotype 10 in breast
cancer incidence, although the low precision of the estimate makes
interpretation difficult.
One limitation of these data is the low concordance of eight tag
SNPs with their blinded repeats, which prevented us from including
them in our analyses. Five of the requested SNPs were found in repeat
regions of the PPARA gene and, therefore, would have been difficult
Fig. 1. Linkage disequilibrium (r2) between six PPARA tag SNPs among
LIBCSP controls.
Table III. Odds Ratios (OR) and 95% Confidence Intervals (CI) for six PPARA polymorphisms and breast cancer among postmenopausal women in the LIBCSP
for conventional and hierarchical models with varying priors
SNP Allelesa Conventionalb Conventionalc Hierarchicald Hierarchicale
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
rs135542 AG 1.07 0.85, 1.35 1.05 0.82, 1.34 1.06 0.84, 1.34 1.06 0.83, 1.34
GG 1.04 0.59, 1.81 1.13 0.63, 2.02 1.13 0.69, 1.83 1.13 0.67, 1.91
rs1800206 CG 1.01 0.71, 1.44 0.93 0.60, 1.46 0.98 0.67, 1.43 0.96 0.64, 1.43
GG 5.07 0.59, 43.71 4.14 0.43, 39.79 1.29 0.58, 2.87 1.47 0.51, 4.27
rs4253623 AG 0.96 0.74, 1.24 1.15 0.86, 1.52 1.14 0.87, 1.49 1.14 0.86, 1.51
GG 0.66 0.30, 1.45 0.61 0.26, 1.43 0.83 0.46, 1.53 0.76 0.38, 1.52
rs4253699 CT 1.13 0.90, 1.42 0.97 0.73, 1.28 1.00 0.77, 1.29 0.99 0.76, 1.29
CC 0.92 0.56, 1.49 0.89 0.49, 1.62 1.02 0.64, 1.62 0.98 0.59, 1.64
rs4253755 AG 1.12 0.86, 1.46 1.06 0.74, 1.52 1.07 0.78, 1.47 1.06 0.76, 1.49
AA 1.36 0.57, 3.27 1.29 0.44, 3.76 1.20 0.62, 2.30 1.22 0.56, 2.69
rs4253760 GT 1.14 0.90, 1.46 1.17 0.85, 1.61 1.13 0.85, 1.49 1.15 0.85, 1.54
GG 1.97 1.14, 3.43 2.19 1.17, 4.13 1.71 1.05, 2.80 1.90 1.10, 3.28
aMinor alleles in bold.
bModels included one SNP and age only.
cAll SNPs plus age in one model.
dAll SNPs exchangeable and prior s2 5 0.169.
eAll SNPs exchangeable and prior s2 5 0.345.
PPARA and breast cancer risk
1947
to genotype successfully. The low concordances found for rs4253730,
rs4253655 and rs135543 with their repeats are not easily explained
and could be the result of genotyping error. Using 95% concordance
rates rather than kappa statistics does not alter the number of SNPs
eligible for inclusion. Two of the unexplained genotyping failures
(rs135543 and rs4253655), however, have concordance rates of
92.0%.
Although these omissions reduced gene coverage, this study still
provides more coverage than previous studies and analyses a well-
characterized population. Only two studies have examined PPARA
haplotypes to date, none of which examined cancer outcomes or in-
cluded more than three SNPs (13,19). Flavell et al. (19) investigated
three SNPs in connection to age of onset and progression of type II
diabetes mellitus, whereas Doney et al. (13) explored the link between
myocardial infarction risk among individuals with type II diabetes
mellitus and two PPARA polymorphisms. Thus, even with reduced
gene coverage, this study advances scientific knowledge of PPARA
and its role in breast cancer incidence.
Reported weight at age 50 and other past exposures may be sub-
jected to recall bias and non-differential misclassification since dis-
ease diagnosis has occurred before exposure ascertainment. This
study examined body size as a potential modifier of the gene’s effect;
therefore, for recall bias to be present, cases and controls would have
to recall their weight differentially by PPARA genotype. Since women
are unlikely to know their PPARA status, recall bias is unlikely to play
a role in these analyses.
Although a benefit of our study is that it is population based, only
73% of cases and controls donated blood. However, the distributions
of risk factors for breast cancer among all women in the study were
comparable with those of women who donated blood (data not
shown). Lastly, the ethnic distribution of our Long Island subjects
differs from that of the American population as a whole, with
92.7% of our study population being Caucasian; thus, results from
this study may not be readily applied to the USA population in gen-
eral. Although the underlying prevalence of specific alleles and ex-
posures may vary with ethnicity, it seems unlikely that the biological
relations with breast cancer among participants in this study will
differ from women in general. In fact, as expected, the minor allele
frequencies differed only slightly between the PGA European Amer-
ican population and our Long Island women, with the greatest differ-
ence noted for rs4253755 (18.2 versus 22.0%, respectively). This
difference is most likely due to PGA’s small sample (n 5 23) for
determining the allele frequencies in European Americans.
Lack of reproducibility among genetic studies has called into ques-
tion the utility of association studies in genetic epidemiology (42).
This is the first study to examine the association between PPARA
polymorphisms and breast cancer development. While our use of
semi-Bayesian techniques minimizes many issues inherent with small
cell sizes, such as large but imprecise effects and low P-values, further
replication is needed to confirm our findings.
In summary, although PPARA has been studied in cardiovascular
disease, no studies have examined PPARA in connection to breast
cancer. This study is the first to investigate its relationship to breast
Table IV. ORs, interaction contrast ratios (ICRs) and 95% CI for six PPARA
polymorphisms and breast cancer by aspirin use in all LIBCSP women under
the dominant inheritance model
Interactiona,b ORc 95% CI ICR 95% CI
rs135542
AA(aspirin use)d 0.92 0.69, 1.23
(AG þ GG)(non-use) 1.09 0.88, 1.36
(AG þ GG)(aspirin use) 0.56 0.39, 0.81 0.45 0.87, 0.04
rs1800206
CC(aspirin use) 0.73 0.57, 0.92
(CG þ GG)(non-use) 1.05 0.71, 1.56
(CG þ GG)(aspirin use) 0.94 0.46, 1.89 0.16 0.59, 0.91
rs4253623
AA(aspirin use) 0.64 0.49, 0.84
(AG þ GG)(non-use) 0.94 0.73, 1.22
(AG þ GG)(aspirin use) 1.07 0.71, 1.61 0.48 0.01, 0.98
rs4263699
TT(aspirin use) 0.60 0.45, 0.80
(CT þ CC)(non-use) 0.85 0.66, 1.09
(CT þ CC)(aspirin use) 0.91 0.62, 1.32 0.46 0.08, 0.84
rs4253755
GG(aspirin use) 0.65 0.50, 0.84
(AG þ AA)(non-use) 0.93 0.68, 1.27
(AG þ AA)(aspirin use) 1.08 0.67, 1.75 0.50 0.05, 1.05
rs4253760
TT(aspirin use) 0.62 0.47, 0.82
(GT þ GG)(non-use) 0.92 0.70, 1.21
(GT þ GG)(aspirin use) 0.97 0.65, 1.44 0.42 0.01, 0.85
aInteractions between aspirin use and each SNP were estimated using separate
logistic regression models that also included main effect terms for the other
PPARA SNPs. All ORs are estimated relative to a common referent group
consisting of aspirin non-users with the referent genotype for each SNP. ICRs
indicate departures from expectations for additive effects of aspirin use and
each SNP on breast cancer risk.
bMinor allele in bold.
cAdjusted for age, measured in 5-year age intervals.
dAspirin use was defined as use at least once per week for 6 months or longer.
Table V. ORs and frequencies by case–control status for 14 PPARA haplotypes relative to all other haplotypes among postmenopausal women in LIBCSP
Haplotype
numbera
rs135542 rs1800206 rs4253623 rs4253699 rs4253755 rs4253760 Control n (%) Case n (%) OR (95% CI)b
1 A C A C A G 55 (5.5) 53 (5.3) 1.01 (0.49, 2.09)
2 A C A C A T 18 (1.9) 32 (3.2) 2.03 (0.71, 5.82)
3 A C A C G G 18 (1.8) 14 (1.4) 0.97 (0.23, 4.18)
4 A C A C G T 55 (5.5) 53 (5.2) 0.89 (0.40, 1.99)
5 A C A T A G 25 (2.5) 32 (3.2) 1.64 (0.61, 4.46)
6 A C A T G G 19 (1.9) 36 (3.6) 2.83 (0.93, 8.65)
7 A C A T G T 414 (41.7) 396 (39.2) 0.92 (0.70, 1.20)
8 A C G C G T 13 (1.5) 10 (1.0) 0.77 (0.12, 4.91)
9 A C G T G T 104 (10.5) 103 (10.2) 0.97 (0.59, 1.59)
10 A G A C G G 11 (1.1) 30 (3.0) 5.02 (1.45, 17.39)
11 A G A T G G 13 (1.3) 8 (0.8) 0.47 (0.08, 2.83)
12 G C A C G T 15 (1.5) 8 (0.8) 0.42 (0.05, 3.55)
13 G C A T G G 11 (1.1) 11 (1.1) 1.07 (0.13, 8.67)
14 G C A T G T 173 (17.4) 182 (18.0) 1.19 (0.79, 1.80)
aHaplotypes with frequency 0.01, minor alleles in bold.
bAdjusted for age, measured in 5-year age intervals.
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cancer risk and interaction by aspirin use and obesity in a large
population-based sample. This study suggests that variants of PPARA
modify the association between breast cancer and aspirin use. Re-
search investigating PPARA’s possible involvement in the inflamma-
tory pathway is needed. We found that among postmenopausal
women carrying the homozygous alleles for rs4253760, the odds of
breast cancer was nearly doubled. These findings warrant further in-
vestigation in an independent cohort.
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